Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
Neurochirurgie ; 69(4): 101459, 2023 Jul.
Article in English | MEDLINE | ID: mdl-37295279

ABSTRACT

INTRODUCTION: Ependymomas in the posterior fossa have poor prognosis. This study reports a single-center pediatric series, focusing on the value of surgical resection. MATERIAL AND METHODS: A single-center retrospective study included all patients operated on by the senior author (CM) for posterior fossa ependymoma from 2002 to 2018. Medical and surgical data were extracted from the hospital's medical database. RESULTS: Thirty-four patients were included. Age ranged from 6 months to 18 years, with a median of 4.7 years. Fourteen patients underwent initial endoscopic third ventriculocisternostomy before the direct surgical resection. Surgical removal was complete in 27 patients. There were 32 surgeries for second-look, local recurrence or metastasis despite complementary chemotherapy and/or radiotherapy. Twenty patients were WHO grade 2 and 14 grade 3. Sixteen patients showed recurrence (47%). Overall survival was 61.8% at a mean 10.1 years' follow-up. Morbidities comprised facial nerve palsy, swallowing disorder, and transient cerebellar syndrome. Fifteen patients had normal schooling, 6 had special assistance; 4 patients reached university, 3 of whom experienced difficulties. Three patients had a job. CONCLUSION: Posterior fossa ependymomas are aggressive tumors. Complete surgical removal is the most important prognostic factor, despite risk of sequelae. Complementary treatment is mandatory, but no targeted therapy has so far proved effective. It is important to continue the search for molecular markers in order to improve outcomes.


Subject(s)
Ependymoma , Child , Humans , Infant , Retrospective Studies , Ependymoma/diagnosis , Ependymoma/surgery , Combined Modality Therapy , Disease Progression
2.
Neurochirurgie ; 66(1): 53-55, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31953073

ABSTRACT

INTRODUCTION: Tumors of the spinal cord are rare and some can be confused with each other. We report a rare spinal cord solitary fibrous tumor/hemangiopericytoma (SFT/HPC), and propose keys to differentiate spinal cord tumors from each other. CASE REPORT: A 67-year-old man presented weakness with recent diffuse sensory disorders in the right lower limb. Spinal MRI revealed a T8-T9 intradural extramedullary mass with spinal cord compression. Gross total resection of a poorly vascularized intradural tumor was achieved. It was an encapsulated extramedullary tumor, which was difficult to separate from the spinal cord due to the presence of pial adhesions. Definitive diagnosis was grade 1 SFT/HPC of the spinal cord. One-year follow-up MRI revealed complete excision without any evidence of residual tumor. CONCLUSION: SFT/HPC is a very rare spinal tumor that can be extramedullary, intramedullary or both. It may perfectly mimic meningioma. The maximal resection is the best treatment, but can be challenging because of the tumor's firm consistency and pial adherences to the spinal cord. Outcome is good in case of gross total resection, but there is a risk of very late recurrence, requiring long-term follow-up.


Subject(s)
Hemangiopericytoma/diagnosis , Spinal Cord Neoplasms/diagnosis , Aged , Diagnosis, Differential , Hemangiopericytoma/surgery , Humans , Magnetic Resonance Imaging , Male , Muscle Weakness/etiology , Neurosurgical Procedures , Pia Mater/diagnostic imaging , Pia Mater/pathology , Sensation Disorders/etiology , Solitary Fibrous Tumors/diagnosis , Spinal Cord Neoplasms/surgery , Tissue Adhesions/diagnostic imaging , Tissue Adhesions/pathology , Treatment Outcome
3.
Virchows Arch ; 475(6): 687-692, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31578606

ABSTRACT

The 2017 World Health Organization (WHO) classification proposes to type and subtype primary adenohypophyseal tumours according to their cell lineages with the aim to establish more uniform tumour groups. The definition of atypical adenoma was removed in favour of high-risk adenoma, and the assessment of proliferative activity and invasion was recommended to diagnose aggressive tumours. Recently, the International Pituitary Pathology Club proposed to replace adenoma with the term of pituitary neuroendocrine tumour (PitNET) to better reflect the similarities between adenohypophyseal and neuroendocrine tumours of other organs. The European Pituitary Pathology Group (EPPG) endorses this terminology and develops practical recommendations for standardised reports of PitNETs that are addressed to histo- and neuropathologists. This brief report presents the results of EPPG's consensus for the reporting of PitNETs and proposes a diagnostic algorithm.


Subject(s)
Glucosyltransferases/metabolism , Glycoproteins/metabolism , Neuroendocrine Tumors/diagnosis , Pituitary Neoplasms/diagnosis , Pituitary Neoplasms/pathology , Consensus , Humans , Neuroendocrine Tumors/pathology , Neurosecretory Systems/pathology , World Health Organization
4.
Endocr Relat Cancer ; 25(9): 795-806, 2018 09.
Article in English | MEDLINE | ID: mdl-30012586

ABSTRACT

Prolactinoma represents the most frequent hormone-secreting pituitary tumours. These tumours appear in a benign form, but some of them can reach an invasive and aggressive stage through an unknown mechanism. Discovering markers to identify prolactinoma proliferative and invading character is therefore crucial to develop new diagnostic/prognostic strategies. Interestingly, members of the TGFß-Activin/BMP signalling pathways have emerged as important actors of pituitary development and adult function, but their role in prolactinomas remains to be precisely determined. Here, using a heterotopic allograft model derived from a rat prolactinoma, we report that the Activins orphan type I receptor ALK7 is ectopically expressed in prolactinomas-cells. Through immunohistological approaches, we further confirm that normal prolactin-producing cells lack ALK7-expression. Using a series of human tumour samples, we show that ALK7 expression in prolactinomas cells is evolutionary conserved between rat and human. More interestingly, our results highlight that tumours showing a robust expression of ALK7 present an increased proliferation as address by Ki67 expression and retrospective analysis of clinical data from 38 patients, presenting ALK7 as an appealing marker of prolactinoma aggressiveness. Beside this observation, our work pinpoints that the expression of prolactin is highly heterogeneous in prolactinoma cells. We further confirm the contribution of ALK7 in these observations and the existence of highly immunoreactive prolactin cells lacking ALK7 expression. Taken together, our observations suggest that Activin signalling mediated through ALK7 could therefore contribute to the hormonal heterogeneity and increased proliferation of prolactinomas.


Subject(s)
Activin Receptors, Type I/metabolism , Pituitary Neoplasms/metabolism , Prolactin/metabolism , Prolactinoma/metabolism , Activins/metabolism , Animals , Humans , Pituitary Neoplasms/pathology , Prolactinoma/pathology , Rats
5.
Endocr Relat Cancer ; 24(4): C5-C8, 2017 04.
Article in English | MEDLINE | ID: mdl-28264912

ABSTRACT

The classification of neoplasms of adenohypophysial cells is misleading because of the simplistic distinction between adenoma and carcinoma, based solely on metastatic spread and the poor reproducibility and predictive value of the definition of atypical adenomas based on the detection of mitoses or expression of Ki-67 or p53. In addition, the current classification of neoplasms of the anterior pituitary does not accurately reflect the clinical spectrum of behavior. Invasion and regrowth of proliferative lesions and persistence of hormone hypersecretion cause significant morbidity and mortality. We propose a new terminology, pituitary neuroendocrine tumor (PitNET), which is consistent with that used for other neuroendocrine neoplasms and which recognizes the highly variable impact of these tumors on patients.


Subject(s)
Adenoma/classification , Neuroendocrine Tumors/classification , Pituitary Neoplasms/classification , Humans
6.
Clin Genet ; 90(6): 550-555, 2016 12.
Article in English | MEDLINE | ID: mdl-27040866

ABSTRACT

Taybi-Linder syndrome (TALS, OMIM 210710) is a rare autosomal recessive disorder belonging to the group of microcephalic osteodysplastic primordial dwarfisms (MOPD). This syndrome is characterized by short stature, skeletal anomalies, severe microcephaly with brain malformations and facial dysmorphism, and is caused by mutations in RNU4ATAC. RNU4ATAC is transcribed into a non-coding small nuclear RNA which is a critical component of the minor spliceosome. We report here four foetuses and four unrelated patients with RNU4ATAC mutations. We provide antenatal descriptions of this rare syndrome including unusual features found in two twin foetuses with compound heterozygosity for two rare mutations who presented with mild intrauterine growth retardation and atypical dysmorphic facial features. We also carried out a literature review of the patients described up to now with RNU4ATAC mutations, affected either with TALS or Roifman syndrome, a recently described allelic disorder.


Subject(s)
Abnormalities, Multiple/genetics , Cardiomyopathies/genetics , Dwarfism/genetics , Fetal Growth Retardation/genetics , Immunologic Deficiency Syndromes/genetics , Mental Retardation, X-Linked/genetics , Microcephaly/genetics , Osteochondrodysplasias/genetics , RNA, Small Nuclear/genetics , Retinal Diseases/genetics , Abnormalities, Multiple/physiopathology , Alleles , Cardiomyopathies/physiopathology , Child , Child, Preschool , Dwarfism/physiopathology , Female , Fetal Growth Retardation/physiopathology , Fetus , Humans , Immunologic Deficiency Syndromes/physiopathology , Infant , Infant, Newborn , Male , Mental Retardation, X-Linked/physiopathology , Microcephaly/physiopathology , Mutation , Osteochondrodysplasias/physiopathology , Phenotype , Primary Immunodeficiency Diseases , Retinal Diseases/physiopathology , Spliceosomes/genetics
7.
Neuroscience ; 311: 382-97, 2015 Dec 17.
Article in English | MEDLINE | ID: mdl-26542996

ABSTRACT

The blood-brain barrier (BBB) is a complex structure that protects the central nervous system from peripheral insults. Understanding the molecular basis of BBB function and dysfunction holds significant potential for future strategies to prevent and treat neurological damage. The aim of our study was (1) to investigate BBB alterations following excitotoxicity and (2) to test the protective properties of melatonin. Ibotenate, a glutamate analog, was injected intracerebrally in postnatal day 5 (P5) rat pups to mimic excitotoxic injury. Animals were than randomly divided into two groups, one receiving intraperitoneal (i.p.) melatonin injections (5mg/kg), and the other phosphate buffer saline (PBS) injections. Pups were sacrificed 2, 4 and 18 h after ibotenate injection. We determined lesion size at 5 days by histology, the location and organization of tight junction (TJ) proteins by immunohistochemical studies, and BBB leakage by dextran extravasation. Expression levels of BBB genes (TJs, efflux transporters and detoxification enzymes) were determined in the cortex and choroid plexus by quantitative PCR. Dextran extravasation was seen 2h after the insult, suggesting a rapid BBB breakdown that was resolved by 4h. Extravasation was significantly reduced in melatonin-treated pups. Gene expression and immunohistochemical assays showed dynamic BBB modifications during the first 4h, partially prevented by melatonin. Lesion-size measurements confirmed white matter neuroprotection by melatonin. Our study is the first to evaluate BBB structure and function at a very early time point following excitotoxicity in neonates. Melatonin neuroprotects by preventing TJ modifications and BBB disruption at this early phase, before its previously demonstrated anti-inflammatory, antioxidant and axonal regrowth-promoting effects.


Subject(s)
Blood-Brain Barrier/drug effects , Melatonin/pharmacology , Neuroprotective Agents/pharmacology , Animals , Animals, Newborn , Blood-Brain Barrier/metabolism , Blood-Brain Barrier/pathology , Capillary Permeability/drug effects , Capillary Permeability/physiology , Disease Models, Animal , Excitatory Amino Acid Agents/toxicity , Gene Expression/drug effects , Glutamic Acid/analogs & derivatives , Glutamic Acid/toxicity , Immunohistochemistry , Random Allocation , Rats, Sprague-Dawley
8.
Neurochirurgie ; 61(2-3): 138-42, 2015.
Article in English | MEDLINE | ID: mdl-24556386

ABSTRACT

BACKGROUND AND PURPOSE: The papillary tumor of the pineal region (PTPR) was described as a distinct new entity for the first time in 2003 by our team and has been included in the last 2007 WHO classification of tumors of the Central Nervous System. We describe the histopathological characterization of PTPR and present a review of the literature. METHODS: The description of the histological and immunological features of PTPR is based on the 2007 WHO classification. RESULTS: PTPR affects both children and adults, and mostly young adults in the third decade. PTPR is a neuroepithelial tumor occurring in the vicinity of the pineal gland, and characterized by its papillary architecture. The papillae are lined by multi-layered cuboidal to columnar epithelioid tumoral cells arranged in perivascular pseudorosettes. Immunohistochemistry shows strong reactivity for cytokeratins, particularly for cytokeratin 18. On electron microscopy, PTPR reveals ultrastructural features indicative of ependymal differentiation, including abundant microvilli at the apical cell pole. The differential diagnosis includes a variety of other papillary tumors, most notably papillary ependymoma, choroid plexus papilloma, papillary meningioma, and metastatic papillary carcinoma in adults. On the basis of ultrastructural and immunohistochemical features, it has been suggested that a PTPR arises from specialized cytokeratin-positive and nestin-positive ependymal cells that are derived from the subcommissural organ. Although the precise histological grading criteria of PTPR remain to be defined, its biological behavior may correspond to WHO grade II or III.


Subject(s)
Brain Neoplasms/pathology , Carcinoma, Papillary/pathology , Ependymoma/pathology , Pineal Gland/pathology , Animals , Brain Neoplasms/diagnosis , Carcinoma, Papillary/diagnosis , Diagnosis, Differential , Ependymoma/diagnosis , Humans , Immunohistochemistry/methods
9.
Neurochirurgie ; 61(2-3): 130-7, 2015.
Article in English | MEDLINE | ID: mdl-24726316

ABSTRACT

Germ cell tumors (GCTs) classically occur in gonads. However, they are the most frequent neoplasms in the pineal region. The pineal location of GCTs may be caused by the neoplastic transformation of a primordial germ cell that has mismigrated. The World Health Organization (WHO) recognizes 5 histological types of intracranial GCTs: germinoma and non-germinomatous tumors including embryonal carcinoma, yolk sac tumor, choriocarcinoma and mature or immature teratoma. Germinomas and teratomas are frequently encountered as pure tumors whereas the other types are mostly part of mixed GCTs. In this situation, the neuropathologist has to be able to identify each component of a GCT. When diagnosis is difficult, use of recent immunohistochemical markers such as OCT(octamer-binding transcription factor)3/4, Glypican 3, SALL(sal-like protein)4 may be required. OCT3/4 is helpful in the diagnosis of germinomas, Glypican 3 in the diagnosis of yolk sac tumors and SALL4 in the diagnosis of the germ cell nature of an intracranial tumor. When the germ cell nature of a pineal tumor is doubtful, the finding of an isochromosome 12p suggests the diagnosis of GCT. The final pathological report should always be confronted with the clinical data, especially the serum or cerebrospinal fluid levels of ß-human chorionic gonadotropin (HCG) and alpha-fetoprotein.


Subject(s)
Biomarkers, Tumor/metabolism , Brain Neoplasms/pathology , Neoplasms, Germ Cell and Embryonal/pathology , Pineal Gland/pathology , Pinealoma/pathology , Teratoma/pathology , Brain Neoplasms/diagnosis , Glypicans/metabolism , Humans , Neoplasms, Germ Cell and Embryonal/diagnosis , Pinealoma/diagnosis , Teratoma/diagnosis
10.
Neurochirurgie ; 61(2-3): 123-9, 2015.
Article in English | MEDLINE | ID: mdl-24975206

ABSTRACT

BACKGROUND AND PURPOSE: Pineal parenchymal tumours (PPTs) and pineal cysts represent one third of the pineal region lesions. PPTs are subdivided into pineocytoma (PC), pineoblastoma (PB) and PPT with intermediate differentiation (PPTID). We report morphological and immunochemical features which permit to grade these tumours. METHODS: The description of histopathological features and grading is based on a large cooperative series and on the WHO 2007 classification. RESULTS: PCs occur in adults between the third and the sixth decade of life. PBs typically occur in children. PPTIDs have a peak incidence in young adults between 20 and 40 years of age. There is no sex preference. PC is characterized by a uniform cell proliferation with large fibrillary pineocytomatous rosettes. PB is a high-density tumour composed of small blue cells with hyper-chromatic, round or carrot shaped nuclei. PPTIDs have lobulated or diffuse patterns. Grading is based on morphological features, count of mitoses and neurofilament protein (NFP) expression. PCs (grade I) have no mitosis and NFP is highly expressed in pineocytomatous rosettes. PBs (grade IV) are high mitotic tumours and present low or no expression of NFPs. PPTIDs are grade II when mitoses are fewer than 6 for 10 high-power fields and NFPs are expressed, and are grade III when mitoses are greater or equal to 6 or are fewer than 6 with NFPs lowly expressed. Pineal cysts may be differentiated from PPTs by the high expression of NFPs and no expression of Ki-67.


Subject(s)
Brain Neoplasms/pathology , Central Nervous System Cysts/pathology , Pineal Gland/pathology , Pinealoma/pathology , Adult , Brain Neoplasms/diagnosis , Central Nervous System Cysts/diagnosis , Cysts , Diagnosis, Differential , Female , Humans , Male , Pinealoma/diagnosis , Young Adult
11.
J Laryngol Otol ; 128(6): 494-8, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24896105

ABSTRACT

OBJECTIVE: Otic barotrauma is common among air travellers and can cause severe otalgia, perforation of the tympanic membrane and hearing loss. Many prevention measures exist, with varying evidence to support their use. There are no data to establish if air travellers are aware of them or indeed use them. We aimed to establish air travellers' knowledge of such prevention measures. METHODS: We surveyed air travellers at two UK airports by means of a questionnaire. Answers to the questionnaire were collected over a two-week period. RESULTS: Overall, 179 air travellers with a mean age of 28 years (range: 15-72 years) completed the questionnaire. There were 66 female and 113 male air travellers. The majority (84 per cent) complained of symptoms while flying and 30 per cent were not aware of any prevention measures. Barotrauma-related symptoms were reported in 25 per cent of air travellers who were unaware of any prevention measures. Nearly all air travellers (86 per cent) indicated that more information regarding prevention measures would be useful. CONCLUSION: Air travellers are often not aware of prevention measures to avoid otic barotrauma, and the majority suffer as a result. Increasing public awareness of simple prevention measures would have a significant impact on air travellers.


Subject(s)
Aircraft , Barotrauma/prevention & control , Ear, Middle/injuries , Health Knowledge, Attitudes, Practice , Travel , Adolescent , Adult , Aerospace Medicine , Aged , Earache/etiology , Earache/prevention & control , Female , Health Education , Humans , Male , Middle Aged , Surveys and Questionnaires , Young Adult
13.
Ultrasound Obstet Gynecol ; 42(5): 596-602, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23371522

ABSTRACT

By review of a series of cases, we set out to identify sonographic features suggestive of an obstructive mechanism in second-trimester fetuses with ventriculomegaly and describe developmental disorders related to pathological differentiation of the diencephalon, mesencephalon and rhombencephalon that lead to obstruction of cerebrospinal fluid flow. We studied retrospectively 11 fetuses referred for severe second-trimester ventriculomegaly of undetermined origin. Neurosonography was performed with detailed analysis of the third ventricle, thalami, cerebral aqueduct and cerebellum. The cerebral imaging data were compared with neuropathological data in eight patients, with a focus on the level and etiology of the obstruction. Parenchymal thinning and reduction of the pericerebral spaces were highly suggestive of ventriculomegaly due to an obstructive mechanism. The ventriculomegaly was related to diencephalosynapsis (thalamic fusion and third ventricle atresia) in five cases and partial/complete aqueduct stenosis in six; it was associated with cerebellar hypoplasia in six cases, including rhombencephalosynapsis in two cases. In nine patients, disorders of the diencephalon, mesencephalon and rhombencephalon were present. In cases of severe isolated ventriculomegaly in which sonographic features are suggestive of an obstructive mechanism, close examination of the third ventricle, thalami, aqueduct of Sylvius and cerebellum may reveal pathological differentiation of the diencephalon, mesencephalon or rhombencephalon, often in combination.


Subject(s)
Brain Stem/diagnostic imaging , Cerebral Ventricles/diagnostic imaging , Fetus/abnormalities , Hydrocephalus/diagnostic imaging , Ultrasonography, Prenatal/methods , Brain Stem/abnormalities , Cerebral Ventricles/abnormalities , Cerebral Ventricles/pathology , Female , Humans , Hydrocephalus/pathology , Pregnancy , Pregnancy Trimester, Second
14.
J Neurooncol ; 112(2): 223-31, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23314823

ABSTRACT

Papillary tumor of the pineal region (PTPR), recently described as a distinct clinicopathological entity, can show aggressive biological behavior. The optimal therapeutic approach of PTPR has not been well defined. The role of surgery, radiotherapy, and chemotherapy in the treatment of PTPR was analyzed in a large multicenter series. In order to determine factors that influence prognosis, outcome data of a series of 44 patients with histopathologically proven PTPR were retrospectively analyzed. Of the 44 patients, 32 were still alive after a median follow-up of 63.1 months. Twelve patients experienced progressive disease, with seven undergoing two relapses and five more than two. Median overall survival (OS) was not achieved. Median progression-free survival (PFS) was 58.1 months. Only gross total resection and younger age were associated with a longer OS, radiotherapy and chemotherapy having no significant impact. PFS was not influenced by gross total resection. Radiotherapy and chemotherapy had no significant effect. This retrospective series confirms the high risk of recurrence in PTPR and emphasizes the importance of gross total resection. However, our data provide no evidence for a role of adjuvant radiotherapy or chemotherapy in the treatment of PTPR.


Subject(s)
Carcinoma, Papillary/mortality , Neoplasm Recurrence, Local/mortality , Pineal Gland/pathology , Pinealoma/mortality , Adolescent , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols , Carcinoma, Papillary/pathology , Carcinoma, Papillary/therapy , Child , Child, Preschool , Combined Modality Therapy , Disease Progression , Female , Follow-Up Studies , Humans , Male , Middle Aged , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/therapy , Neoplasm Staging , Pinealoma/pathology , Pinealoma/therapy , Prognosis , Radiosurgery , Radiotherapy, Adjuvant , Survival Rate , Young Adult
16.
Neuropathol Appl Neurobiol ; 38(1): 87-94, 2012 Feb.
Article in English | MEDLINE | ID: mdl-21696422

ABSTRACT

AIMS: Pineal parenchymal tumours (PPTs) are rare neoplasms that are divided into pineocytoma (PC), pineoblastoma (PB) and PPT of intermediate differentiation (PPTID). Factors affecting the survival of patients with PPTs are morphological subtype and histological grading according to mitotic index and neurofilament immunostaining. Grading criteria to distinguish PPTIDs are difficult to define, particularly when using small specimens. The Ki67 labelling index (LI) might be helpful in distinguishing between grade II and III PPTIDs. Our study was performed to assess the predictive value of the Ki67 LI in a large cooperative series of PPTs and to evaluate whether inclusion of this data would improve and refine the World Health Organization classification. METHODS: A retrospective analysis of 33 PPTs was performed. The histological features of the tumours were reviewed and Ki67 LI scoring was evaluated by immunohistochemistry. Data were correlated with the patients' survival. RESULTS: The mean Ki67 LI was significantly different for tumour grades (0 in PC, 5.2 ± 0.4 in PPTID grade II, 11.2 ± 2.0 in PPTID grade III, 36.4 ± 6.2 in PB; P < 0.0001). However, there was no statistically significant difference in either overall or disease-free survival evaluated by the Kaplan-Meier method for patients with different grade tumours or Ki67 LI, possibly due to the different clinical management of patients in different centres. CONCLUSIONS: The Ki67 LI may be a useful additional tool for grading PPTs, more particularly in small tumour samples.


Subject(s)
Brain Neoplasms/pathology , Ki-67 Antigen/analysis , Neoplasm Grading/methods , Pineal Gland/pathology , Pinealoma/pathology , Adult , Aged , Biomarkers, Tumor/analysis , Brain Neoplasms/metabolism , Brain Neoplasms/mortality , Child , Female , Humans , Immunohistochemistry , Kaplan-Meier Estimate , Ki-67 Antigen/biosynthesis , Male , Middle Aged , Pineal Gland/metabolism , Pinealoma/metabolism , Pinealoma/mortality , Young Adult
17.
Rev Mal Respir ; 27(7): 764-9, 2010 Sep.
Article in French | MEDLINE | ID: mdl-20863979

ABSTRACT

INTRODUCTION: Pulmonary metastases from meningioma are rare and present with specific clinical and radiological features. The diagnostic and therapeutic management of metastatic meningioma illustrate the concept of orphan thoracic oncology. CASE REPORT: We report the case of a 58-year-old male, former smoker, with a previous history of atypical meningioma and resected lung adenocarcinoma. During oncologic surveillance, a computed-tomography scan disclosed multiple well-defined homogeneous nodules in the right lung. These nodules were hypermetabolic at positron-emission tomography with fluorodesoxyglucose. Pathological examination of metastasectomy specimens revealed metastatic malignant meningioma. CONCLUSIONS: Pulmonary metastases may occur in malignant meningioma. Twenty-one cases have been reported over the past 20 years. As for all rare tumours, multidisciplinary consensus is mandatory, in the absence of evidence-based recommendations based on prospective trials or observational studies.


Subject(s)
Lung Neoplasms/secondary , Meningeal Neoplasms/pathology , Meningioma/secondary , Humans , Lung Neoplasms/diagnosis , Lung Neoplasms/therapy , Male , Meningioma/diagnosis , Meningioma/therapy , Middle Aged
19.
SELECTION OF CITATIONS
SEARCH DETAIL
...